By activating Toll-Like Receptor (TLR)4 and TLR9, they promote specific anti-tumor immune responses, including CD4+ and CD8+ T cell responses and IFN-γ responses in a melanoma mouse model (Junqueira et al., 2012). Here, CD8A is linked to neoplasm.